Cocaine and methamphetamine use psychedelic and ketamine research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
13 registered studies are counted for cocaine and methamphetamine use. By compound: 8 psilocybin, 1 MDMA and 4 ketamine. By registry status: 2 recruiting, 3 not yet recruiting, 2 active, not recruiting, 3 completed, 2 terminated and 1 suspended. By phase: 3 early phase 1, 3 phase 1 and 7 phase 2. Reported start years run from 2011 (earliest) to 2027 (latest).
Studies are matched when the title names cocaine, methamphetamine or stimulant use. MDMA (3,4-methylenedioxymethamphetamine) is a different compound and is not matched by the word methamphetamine. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 13 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 8 |
| MDMA | 1 |
| Ketamine | 4 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 2 | 15% |
| Not yet recruiting | 3 | 23% |
| Active, not recruiting | 2 | 15% |
| Completed | 3 | 23% |
| Terminated | 2 | 15% |
| Suspended | 1 | 8% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 3 | 23% |
| Phase 1 | 3 | 23% |
| Phase 2 | 7 | 54% |
Countries
Country is taken from the study's linked research site. 1 of 13 records have no country on file. The top 2 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 11 | 85% |
| Switzerland | 1 | 8% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 7 |
| 2020 to 2023 | 3 |
| 2015 to 2019 | 1 |
| 2010 to 2014 | 2 |
Study design
- 13 interventional and 0 observational studies.
- Median planned or actual enrolment is 40 participants (range 8 to 120, across 13 records that report it).
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Psilocybin for Methamphetamine Use Disorder | NCT07774702 | Not yet recruiting | Phase 2 | 2027-02-01 | Psilocybin |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV | NCT07756736 | Not yet recruiting | Phase 2 | 2026-11-01 | Psilocybin |
| Safety Profile of Psilocybin for Cocaine Use Disorder | NCT06102434 | Suspended | Early Phase 1 | 2026-02-01 | Psilocybin |
| Psilocybin for Methamphetamine Addiction | NCT06899594 | Recruiting | Early Phase 1 | 2025-04-04 | Psilocybin |
| PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study | NCT06666010 | Not yet recruiting | Phase 2 | 2025-01-01 | Psilocybin |
| Ketamine for Methamphetamine Use Disorder | NCT06496750 | Active, not recruiting | Phase 2 | 2024-09-11 | Ketamine |
| Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction | NCT06125054 | Recruiting | Phase 2 | 2024-02-05 | Ketamine |
| Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder | NCT05322954 | Terminated | Phase 1 | 2023-03-03 | Psilocybin |
| Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder | NCT04982796 | Active, not recruiting | Phase 1 | 2022-07-07 | Psilocybin |
| Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function | NCT05379959 | Completed | Early Phase 1 | 2022-05-11 | MDMA |
| Psilocybin-facilitated Treatment for Cocaine Use | NCT02037126 | Completed | Phase 2 | 2015-05-01 | Psilocybin |
| The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence | NCT01535937 | Terminated | Phase 1 | 2012-02-01 | Ketamine |
| Glutamatergic Modulation of Cocaine-related Deficits | NCT01790490 | Completed | Phase 2 | 2011-02-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | Ketamine
Other condition hubs
Depression | Treatment-resistant depression | Bipolar disorder | Post-traumatic stress disorder | Alcohol use disorder | Opioid use disorder | Tobacco and nicotine use | Anxiety | Cancer and end-of-life distress | Obsessive-compulsive disorder | Eating disorders | Headache and migraine | Chronic pain | Suicidal ideation and suicide risk